BioSpace News Archive

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 fourth quarter and full year financial results on Tuesday, March 1, 2022 , after the close of the U.S. financial markets.

Arcus Biosciences, Inc., a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate at the following upcoming investor conferences.

Masimo announced its financial results for the fourth quarter and full-year ended January 1, 2022.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) for Bucillamine for the prevention of ischemia–reperfusion injury (“IRI”) during liver transplantation.

Bristol-Myers Squibb Company announced that it has priced a public offering of senior unsecured notes in a combined aggregate principal amount of $6 billion.

TC Biopharm (Holdings) PLC (“TC Biopharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), today announced the closing of its previously announced initial public offering of 4,117,648 American Depositary Shares (the “ADSs”) and warrants (the “Warrants”) to purchase up to 8,235,296 ADSs.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced plans to expand its commercial network across Asia with the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong.

Rakuten Medical, Inc. (Rakuten Medical) and Shimadzu Corporation (Shimadzu) today announced enrollment of the first patient in the phase 2 clinical trial of ASP-1929 photoimmunotherapy with fluorescence imaging (Study number: ASP-1929-103) at the National Cancer Institute of the National Institutes of Health in the United States.

Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on IV tramadol.

Senseonics Holdings, Inc. announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Tuesday, March 1, 2022.